The Microbiota–Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders
International Journal of Endocrinology · 2026-01 · 2026 (1)
DOI: 10.1155/ije/7761643 ↗Abstract
The gut microbiota (GM) modulates host energy balance, glucose–lipid metabolism, and enteroendocrine signaling through metabolite–receptor axes that include short‐chain fatty acids (SCFAs) acting on FFAR2/FFAR3 (GPR43/GPR41), microbially transformed bile acids signaling via FXR/TGR5, and amino‐acid/choline‐derived compounds such as imidazole propionate (ImP) and trimethylamine N‐oxide (TMAO). These pathways regulate incretin biology (GLP‐1/PYY), insulin sensitivity, hepatic glucose output, adipose lipolysis, and appetite, thereby shaping risk and progression of Type 2 diabetes mellitus (T2DM), obesity, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and related conditions. Here, we synthesize mechanistic and translational evidence, highlight bidirectional drug–microbiome interactions (GLP‐1 receptor agonists), and review interventions spanning diet, pre/probiotics, fecal microbiota transplantation (FMT), and pharmacologic targeting of bile‐acid and SCFA pathways. Together, these findings support precision strategies that profile GM–metabolite signatures (e.g., SCFAs, secondary bile acids, and ImP TMAO) to guide prevention and therapy in metabolic and gastrointestinal disease.
EUVIMED